Toll Free: 1-888-928-9744

Encephalomyelitis - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Encephalomyelitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H1 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in IND/CTA Filed, Preclinical and Discovery stages are 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Encephalomyelitis - Overview Encephalomyelitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Encephalomyelitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Encephalomyelitis - Companies Involved in Therapeutics Development Aurigene Discovery Technologies Ltd Bionure Farma SL Biovista Inc Momenta Pharmaceuticals Inc OSE Immunotherapeutics Philogen SpA Encephalomyelitis - Drug Profiles BN-201 - Drug Profile Product Description Mechanism Of Action R&D Progress FR-104 - Drug Profile Product Description Mechanism Of Action R&D Progress JM-4 - Drug Profile Product Description Mechanism Of Action R&D Progress M-254 - Drug Profile Product Description Mechanism Of Action R&D Progress Preimplantation Factor - Drug Profile Product Description Mechanism Of Action R&D Progress PSA-20 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Tetravil - Drug Profile Product Description Mechanism Of Action R&D Progress thymulin - Drug Profile Product Description Mechanism Of Action R&D Progress WEHI-345 - Drug Profile Product Description Mechanism Of Action R&D Progress Encephalomyelitis - Dormant Projects Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Encephalomyelitis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Encephalomyelitis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Encephalomyelitis - Pipeline by Bionure Farma SL, H1 2017 Encephalomyelitis - Pipeline by Biovista Inc, H1 2017 Encephalomyelitis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017 Encephalomyelitis - Pipeline by OSE Immunotherapeutics, H1 2017 Encephalomyelitis - Pipeline by Philogen SpA, H1 2017 Encephalomyelitis - Dormant Projects, H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify